

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 FEBRUARY 2018

ERRATUM

This erratum corrects the 1 February 2018 Schedule by retaining as a pharmaceutical benefit **Tenecteplase** (items 8526R, 8527T). The change was requested by the manufacturer after concerns were raised by prescribers that the benefit was essential for treatment of acute myocardial infarction in rural and remote areas. Corrected data to follow.

▪ **TENECTEPLASE**

Note Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Restricted benefit

Acute myocardial infarction

Clinical criteria:

- The treatment must be administered within 12 hours of onset of attack.

tenecteplase 8000 units (40 mg) injection [1 vial] (& inert substance diluent [8 mL syringe], 1 pack

8526R	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	1	1861.19	39.50	Metalyse [BY]

tenecteplase 10 000 units (50 mg) injection [1 vial] (& inert substance diluent [10 mL syringe], 1 pack

8527T	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer
NP	1	1955.88	39.50	Metalyse [BY]